5/26/2015 - 11:54 AM EST - IntelliPharmaCeutics International Inc. : announced that the United States Food and Drug Administration ("FDA") has reviewed the Company's request for Fast Track designation for its abuse deterrent Rexista™ Oxycodone XR (Oxycodone HCl) extended-release tablets development program incorporating its Paradoxical OverDose Resistance Activating System ("PODRAS™") and has concluded that it meets the criteria for Fast Track designation. IntelliPharmaCeutics International Inc.
shares T.I are trading up $0.16 at $4.21.
